Biosimilar Uptake in Europe / Big Challenges; Bigger Rewards
Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving biosimilar uptake in Europe. Since the…
Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving biosimilar uptake in Europe. Since the…
The United Arab Emirates’ Cabinet, the de facto executive branch of the federation, recently announced a set of decisions and legislation to support health research as a pillar of the…
As anti-vaccination sentiments resurface globally, so have once-eradicated diseases. This situation is especially prevalent in Romania and has become a severe economic, social, and health threat. Romania’s Struggle with…
The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for…
BIO’s Greg Frank outlines the alarming growth of drug-resistant infections and the steps that need to be taken to combat this rapidly emerging global health threat. Drug-resistant superbugs are…
PharmaBoardroom sat down with more than 25 biotech CEOs in China in 2019. We analyzed the contents of the interviews and found the following recurring themes at the top of…
Digital health deal values in biopharma jumped to USD 6.4 billion in 2019, largely thanks to software company Dassault Systemes Americas Corp.’s USD 5.9 billion acquisition of health tech company…
With so many wild predictions being bandied around about AI’s potential to radically transform healthcare for the better, it is easy to lose sight of the fact that materialization of…
As data and information proliferate at an exponential pace, many industries have turned to artificial intelligence to make sense of this information and deliver meaningful insights that can enhance performance.…
On the supply side, AI appears to herald the prospect of de-risking the drug discovery process and doing away with many of the traditional time-consuming approaches at a juncture when…
The AI in Life Sciences Market was valued at USD 902.1 million in 2019 by Mordor Intelligence and is projected to expand at an impressive 20 percent compound annual growth…
When life sciences companies decide to transfer the production of new drug to Puerto Rico, extend an existing production line, or simply sustain existing operations, they can count on the…
See our Cookie Privacy Policy Here
